Chemistry Reference and  Research
           
 
Periodic Table
- standard table
- large table
 
Chemical Elements
- by name
- by symbol
- by atomic number
 
Chemical Properties
 
Chemical Reactions
 
Organic Chemistry
 
Branches of Chemistry
Analytical chemistry
Biochemistry
Computational Chemistry
Electrochemistry
Environmental chemistry
Geochemistry
Inorganic chemistry
Materials science
Medicinal chemistry
Nuclear chemistry
Organic chemistry
Pharmacology
Physical chemistry
Polymer chemistry
Supramolecular Chemistry
Thermochemistry

Anorectic

Anorectics, anorexigenics or appetite suppressants, are substances which reduce the desire to eat ("anorectic", from the Greek an- = "not" and oreg- = "extend, reach").

Used on a short term basis clinically to treat obesity, some appetite suppressants are also available over the counter. Drugs of this class are frequently stimulants of the phenethylamine family, related to amphetamine (speed). Indeed, amphetamine itself was sold commercially as an appetite suppressant until it was outlawed in most parts of the world in the late 1950s due to increasing exploitation of its stimulant properties ("abuse"). Many amphetamines produce side effects including addiction, tachycardia and hypertension, making prolonged unsupervised use dangerous.

Epidemics of fatal pulmonary hypertension and heart valve damage associated with anorectic agents have led to the withdrawal of products from the market. This was the case with aminorex in the 1960s, and again in the 1990s with fenfluramine (see: Fen-phen). Likewise, association of the related appetite suppressant phenylpropanolamine with hemorrhagic stroke led the FDA to request its withdrawal from the market in the United States in 2000, and similar concerns regarding ephedrine resulted in an FDA ban on its inclusion in dietary supplements, in 2004.

In spite of these precedents, numerous related compounds are still marketed today as appetite suppressants. These include phentermine (Fastin®, Adipex®, Ionamin® and others), diethylpropion (Tenuate®), phendimetrazine (Prelu-2®), benzphetamine (Didrex®) and others. Sibutramine (Medaria®, Reductil®) is a recent addition, which is used with orlistat by doctors to control obesity. The new cannabinoid receptor antagonist Rimonabant (Acomplia®) will be available in 2006.

References

  • Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. N Engl J Med 1996;335:609. Fulltext. PMID 8692238.
  • Fishman AP. Aminorex to Fen/Phen: An Epidemic Foretold. Circulation 1999;99:156. Fulltext. PMID 9884392.

External links

01-04-2007 01:16:19
The contents of this article are licensed from Wikipedia.org under the GNU Free Documentation License. How to see transparent copy